IL6R and COVID-19: The Institute quick reaction at the mounting epidemics, even in absence of COVID-19 patients, achieved highly relevant research results and in particular highlighted the anaphylactoid component of the Acute Respiratory Distress Syndrome (ARDS) and the possibility of introducing anti-IL-6/IL-6R axis available drugs in particular Tocilizumab during the cytokine storm with drastic reduction of the Intensive Care Units (ICU) occupancy and the following intubation (9–11).